2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial

被引:81
|
作者
Al-Mrabeh, Ahmad [1 ]
Hollingsworth, Kieren G. [1 ]
Shaw, James A. M. [2 ]
McConnachie, Alex [3 ]
Sattar, Naveed [4 ]
Lean, Michael E. J. [5 ]
Taylor, Roy [1 ]
机构
[1] Newcastle Univ, Magnet Resonance Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Regenerat Med, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[3] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[4] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland
来源
LANCET DIABETES & ENDOCRINOLOGY | 2020年 / 8卷 / 12期
关键词
D O I
10.1016/S2213-8587(20)30303-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The pancreas is small and irregular in shape in people with type 2 diabetes. If these abnormalities are caused by the disease state itself rather than being a predisposing factor, remission of type 2 diabetes should restore normal pancreas morphology. The objective of this study was to determine whether changes in pancreas volume and shape occurred during 2 years of remission. Methods For this post-hoc analysis, we included a subset of adult participants of the Diabetes Remission Clinical Trial (DiRECT), who had type 2 diabetes and were randomly assigned to a weight management intervention or routine diabetes management. Intervention group participants were categorised as responders (HbA(1c) <6.5% [48 mmol/mol] and fasting blood glucose <7.0 mmol/L, off all anti-diabetes medication) and non-responders, who were classified as remaining diabetic. Data on pancreas volume and irregularity of pancreas border at baseline, 5 months, 12 months, and 24 months after intervention were compared between responders and non-responders; additional comparisons were made between control group participants with type 2 diabetes and a non-diabetic comparator (NDC) group, who were matched to the intervention group by age, sex, and post-weight-loss weight, to determine the extent of any normalisation. We used a mixed-effects regression model based on repeated measures ANOVA with correction for potential confounding. Magnetic resonance techniques were employed to quantify pancreas volume, the irregularity of the pancreas borders, and intrapancreatic fat content. beta-cell function and biomarkers of tissue growth were also measured. Findings Between July 25, 2015, and Aug 5, 2016, 90 participants with type 2 diabetes in the DiRECT subset were randomly assigned to intervention (n=64) or control (n=26) and were assessed at baseline; a further 25 non-diabetic participants were enrolled into the NDC group. At baseline, mean pancreas volume was 61.7 cm(3) (SD 16.0) in all participants with type 2 diabetes and 79.8 cm(3) (14.3) in the NDC group (p<0.0001). At 24 months, pancreas volume had increased by 9.4 cm(3) (95% CI 6.1 to 12.8) in responders compared with 6.4 cm(3) (2.5 to 10.3) in non-responders (p=0.0008). Pancreas borders at baseline were more irregular in participants with type 2 diabetes than in the NDC group (fractal dimension 1.138 [SD 0.027] vs 1.097 [0.025]; p<0.0001) and had normalised by 24 months in responders only (1.099 [0.028]). Intrapancreatic fat declined by 1.02 percentage points (95% CI 0.53 to 1.51) in 32 responders and 0.51% (-0.17 to 1.19) in 13 non-responders (p=0.23). Interpretation These data show for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of type 2 diabetes by weight loss-induced remission. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [1] 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial (vol 8, pg 939, 2020)
    Al-Mrabeh, A.
    Hollingsworth, K. G.
    Shaw, J. A. M.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : E7 - E7
  • [2] Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
    Lean, Michael E. J.
    Leslie, Wilma S.
    Barnes, Alison C.
    Brosnahan, Naomi
    Thom, George
    McCombie, Louise
    Peters, Carl
    Zhyzhneuskaya, Sviatlana
    Al-Mrabeh, Ahmad
    Hollingsworth, Kieren G.
    Rodrigues, Angela M.
    Rehackova, Lucia
    Adamson, Ashley J.
    Sniehotta, Falko F.
    Mathers, John C.
    Ross, Hazel M.
    McIlvenna, Yvonne
    Welsh, Paul
    Kean, Sharon
    Ford, Ian
    McConnachie, Alex
    Messow, Claudia-Martina
    Sattar, Naveed
    Taylor, Roy
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (05): : 344 - 355
  • [3] Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
    Lean, Michael E. J.
    Leslie, Wilma S.
    Barnes, Alison C.
    Brosnahan, Naomi
    Thom, George
    McCombie, Louise
    Peters, Carl
    Zhyzhneuskaya, Sviatlana
    Al-Mrabeh, Ahmad
    Hollingsworth, Kieren G.
    Rodrigues, Angela M.
    Rehackova, Lucia
    Adamson, Ashley J.
    Sniehotta, Falko F.
    Mathers, John C.
    Ross, Hazel M.
    McIlvenna, Yvonne
    Stefanetti, Renae
    Trenell, Michael
    Welsh, Paul
    Kean, Sharon
    Ford, Ian
    McConnachie, Alex
    Sattar, Naveed
    Taylor, Roy
    LANCET, 2018, 391 (10120): : 541 - 551
  • [4] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Tuttle, Katherine R.
    Cherney, David Z. I.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11): : 774 - 785
  • [5] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes Post hoc analysis of an open-label, randomised, phase 3 trial
    Schuerfeld, Robin
    DIABETOLOGIE, 2023, 19 (02): : 205 - 207
  • [6] EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE VERSUS PREVIOUSLY TREATED ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 2-YEAR, OPEN-LABEL STUDY
    Correll, C. U.
    Tocco, M.
    Goldman, R.
    Pikalov, A.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 206 - 206
  • [7] 2-year Results of the Diabetes Remission Clinical Trial (DiRECT) Study
    Jecht, Michael
    DIABETOLOGE, 2019, 15 (04): : 349 - 350
  • [8] Risperidone in children with disruptive behavior disorders: A 2-year open-label trial
    Reyes-Harde, M
    Croonenberghs, J
    Eerdekens, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S274 - S274
  • [9] Lixisenatide and renal outcomes in patients with type 2 diabetes: a post-hoc analysis of the ELIXA trial
    Muskiet, M. H. A.
    Heerspink, H. J. L.
    Tonneijck, L.
    Huang, Y.
    Liu, M.
    Saremi, A.
    van Raalte, D. H.
    DIABETOLOGIA, 2018, 61 : S40 - S40
  • [10] LONG-TERM EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE VERSUS ANTIPSYCHOTIC-EXPOSED ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 2-YEAR, OPEN-LABEL STUDY
    Correll, Christoph U.
    Goldman, Robert S.
    Tocco, Michael
    Pikalov, Andrei A.
    Hsu, Jay
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S236 - S236